A PHASE II STUDY OF ANTI‐PD‐1 SINTILIMAB IN COMBINATION WITH CHIDAMIDE AND AZACITIDINE IN REFRACTORY AND RELAPSED PERIPHERAL T‐CELL LYMPHOMA. (17th June 2021)